Anavex Lf SC (AVXL)

May 15, 2025, 8:49 PM EDT - 21 days ago

Does Anavex's Alzheimer's Drug Actually Confer Benefit?

May 15, 2025, 12:21 PM EDT - 21 days ago

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)

May 14, 2025, 7:30 AM EDT - 22 days ago

Anavex Life Sciences to Participate at Upcoming Healthcare Conferences

May 13, 2025, 9:25 AM EDT - 23 days ago

Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 23 days ago

Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 4 weeks ago

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025

May 1, 2025, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Apr 30, 2025, 7:30 AM EDT - 5 weeks ago

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Apr 23, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Apr 21, 2025, 7:30 AM EDT - 6 weeks ago

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Apr 5, 2025, 11:30 AM EDT - 2 months ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Mar 31, 2025, 7:30 AM EDT - 2 months ago

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 24, 2025, 7:30 AM EST - 3 months ago

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Feb 14, 2025, 6:02 PM EST - 3 months ago

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 12, 2025, 3:13 PM EST - 4 months ago

Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025

Feb 12, 2025, 9:59 AM EST - 4 months ago

Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript

Feb 12, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Feb 5, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Jan 27, 2025, 7:30 AM EST - 4 months ago

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Jan 15, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Jan 13, 2025, 7:30 AM EST - 5 months ago

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Jan 12, 2025, 11:21 AM EST - 5 months ago

Playing The Odds Of Anavex Alzheimer's Drug Approval

Jan 6, 2025, 7:30 AM EST - 5 months ago

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 27, 2024, 7:30 AM EST - 5 months ago

Anavex Life Sciences: Jumping In On-Time Ahead Early Alzheimer's Decision

Dec 26, 2024, 10:31 AM EST - 5 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA PYPD

Dec 24, 2024, 8:50 AM EST - 5 months ago

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 23, 2024, 10:23 AM EST - 5 months ago

Anavex Life Sciences Corp. (AVXL) Q4 2024 Earnings Call Transcript

Dec 23, 2024, 7:30 AM EST - 5 months ago

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Dec 23, 2024, 7:00 AM EST - 5 months ago

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Dec 16, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Dec 9, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

Nov 26, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA

Nov 25, 2024, 7:30 AM EST - 6 months ago

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal

Nov 6, 2024, 5:10 AM EST - 7 months ago

Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

Oct 31, 2024, 4:00 AM EDT - 7 months ago

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024

Oct 17, 2024, 7:30 AM EDT - 8 months ago

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Sep 3, 2024, 7:30 AM EDT - 9 months ago

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 6, 2024, 12:19 PM EDT - 10 months ago

Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 10 months ago

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

Jul 30, 2024, 7:30 AM EDT - 11 months ago

Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference

Jul 28, 2024, 5:00 PM EDT - 11 months ago

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

May 22, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences Announces Expansion of Leadership Team

May 14, 2024, 7:30 AM EDT - 1 year ago

Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

May 13, 2024, 1:45 PM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses of $500,000 to Contact the Firm